Your session is about to expire
← Back to Search
Nicotine Preloading for Quitting Smoking
Study Summary
This trial is testing if starting nicotine replacement therapy (NRT) earlier than usual may help smokers who are struggling with dependence, cravings, and low confidence to quit successfully. Sixty participants will be randomly assigned to either the control group (standard NRT counseling) or the active group (starting NRT 3 weeks before quit date). The investigators will examine differences in quit attempts and biochemically validated smoking abstinence between the two groups at weeks 8, 12, and 16.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You smoke at least 5 cigarettes per day.I have been diagnosed with HIV.I am 18 years old or older.I am currently using medication to help me stop smoking.I have not been hospitalized for medical or mental health issues in the last 30 days.I have thought about suicide or attempted it in the past year.I am willing to use a nicotine patch.I have been diagnosed with HIV.I am 18 years old or older.I am willing to use a nicotine patch.I am ready to quit smoking within the next 30 days.
- Group 1: Preloading
- Group 2: Standard treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other examples of similar medical trials using Nicoderm CQ 21Mg/24Hr Transdermal System?
"Currently, there are 74 clinical trials underway for Nicoderm CQ 21Mg/24Hr Transdermal System. Of these studies, 5 are in Phase 3. Most of the research being done on Nicoderm CQ 21Mg/24Hr Transdermal System is happening Green Bay, Wisconsin; however, 209 other locations across the world are also conducting trials."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- Brown University School of Public Health: < 48 hours
Typically responds via
Share this study with friends
Copy Link
Messenger